Meta 10C is an upgraded metabolically armed cell therapy platform, which incorporates our Meta 10 technology and has demonstrated the potential to significantly enhance the efficacy of immune cell therapy. The Meta 10C platform aims to develop metabolically enhanced cell therapies, including CAR-T, TCR-T, TILs, and CAR-NK. Our Meta 10C cell therapies have shown excellent therapeutic efficacy in multiple mouse models of solid tumors, lung cancer metastasis models, and xenograft tumor models.
Our Meta 10C metabolism-enhancing cell therapy technology has entered the clinical stage, and we have initiated IIT clinical trials for our metabolism-enhancing CAR-T therapy in collaboration with a team led by Professor Huang He at the First Affiliated Hospital of Zhejiang University. Additionally, we have a robust preclinical research program to further expand our Meta 10C metabolism-enhancing cell therapy pipeline. This cell therapy platform has the potential to collaborate with other pharmaceutical companies to develop innovative cell therapies for cancer treatment.
